Table 1.
Baseline Characteristics of Study Participants, Hospital Israelita Albert Einstein, São Paulo, Brazil, from January 1, 2021, to August 3, 2021
| Charaacterstics | Unvaccinated (n = 1,512) |
2 Doses of CoronaVac Vaccine (n = 6,385) |
2 Doses of ChAdOx1 Vaccine (n = 5,916) |
Total (13,813) |
P
Value |
|---|---|---|---|---|---|
| Sex, no. (%) | <.0001 a | ||||
| Female | 1,043 (69.2) | 4,672 (73.2) | 4,090 (69.1) | 9,805 (71.0) | |
| Male | 465 (30.8) | 1,710 (26.8) | 1,826 (30.9) | 4,001 (29.0) | |
| Missing | 4 (0.26) | 3 (0.05) | 0 (0) | 7 (0.05) | |
| Age, median y | <.0001 b | ||||
| Median (IQR) | 32 (26–38) | 36 (30–42) | 35 (28–42) | 35 (29–42) | |
| Minimum–Maximum | 18–84 | 18–82 | 18–83 | 18–84 | |
| Job type | <.0001 a | ||||
| No direct patient contact | 1,174 (77.6) | 1,333 (20.9) | 4,603 (77.8) | 7,110 (51.5) | |
| Direct patient facing | 338 (22.4) | 5,052 (79.1) | 1,313 (22.2) | 6,703 (48.5) | |
| Comorbidity c | <.0001 a | ||||
| No | 752 (79.7) | 3,568 (75.1) | 3,683 (72.3) | 8,003 (74.2) | |
| Yes | 191 (20.3) | 1,181 (24.9) | 1,411 (27.7) | 2,783 (25.8) | |
| Hypertension c | <.0001 a | ||||
| No | 901 (95.5) | 4,391 (92.5) | 4,651 (91.3) | 9,943 (92.2) | |
| Yes | 42 (4.5) | 358 (7.5) | 443 (8.7) | 843 (7.8) | |
| Diabetes mellitus c | .0856 a | ||||
| No | 929 (98.5) | 4,645 (97.8) | 4,962 (97.4) | 10,536 (97.7) | |
| Yes | 14 (1.5) | 104 (2.2) | 132 (2.6) | 250 (2.3) | |
| Obesity c | .0102 a | ||||
| No | 871 (92.4) | 4,331 (91.2) | 4,575 (89.8) | 9,777 (90.6) | |
| Yes | 72 (7.6) | 418 (8.8) | 519 (10.2) | 1,009 (9.4) | |
| Dyslipidemia c | .0126 a | ||||
| No | 911 (96.6) | 4,479 (94.3) | 4,804 (94.3) | 10,194 (94.5) | |
| Yes | 32 (3.4) | 270 (5.7) | 290 (5.7) | 592 (5.5) | |
| Asthma c | .0984 a | ||||
| No | 908 (96.3) | 4,554 (95.9) | 4,846 (95.1) | 10,308 (95.6) | |
| Yes | 35 (3.7) | 195 (4.1) | 248 (4.9) | 478 (4.4) | |
| Follow-up between COVID-19 vaccine doses, d | <.0001 d | ||||
| Median (IQR) | … | 25 (22–27) | 84 (80–88) | 35 (25–84) | |
| Minimum–Maximum | … | 15–172 | 50–164 | 15–172 | |
| Follow-up period, d e | <.0001 b | ||||
| Median (IQR) | 214 (214–214) | 151 (144–154) | 78 (73–83) | 138 (78–153) | |
| Minimum–Maximum | 17–214 | 1–176 | 1–118 | 1–214 | |
| SARS-COV-2 infection (by PCR) | <.0001 a | ||||
| No | 1,421 (94.0) | 6,194 (97.0) | 5,873 (99.3) | 13,488 (97.6) | |
| Yes | 91 (6.0) | 191 (3.0) | 43 (0.7) | 325 (2.4) | |
| No. of hospitalizations | .0048 f | ||||
| 0 | 1,501 (99.3) | 6,371 (99.8) | 5,904 (99.8) | 13,776 (99.7) | |
| 1 | 11 (0.7) | 14 (0.2) | 11 (0.2) | 36 (0.3) | |
| 2 | 0 (0.0) | 0 (0.0) | 1 (0.0) | 1 (0.0) | |
| Length of hospital stay, d | .0154 b | ||||
| Median (IQR) | 10 (7–21) | 4 (3–6) | 6 (3–9) | 6 (3–10) | |
| Minimum–Maximum | 1–40 | 1–7 | 2–20 | 1–40 | |
| ICU | .3392 f | ||||
| No | 6 (54.5) | 11 (78.6) | 10 (83.3) | 27 (73.0) | |
| Yes | 5 (45.5) | 3 (21.4) | 2 (16.7) | 10 (27.0) | |
| Mechanical ventilation | .0050 f | ||||
| No | 7 (63.6) | 14 (100.0) | 12 (100.0) | 33 (89.2) | |
| Yes | 4 (36.4) | 0 (0.0) | 0 (0.0) | 4 (10.8) | |
Note. ChAdOx1 vaccine, Oxford-AstraZeneca vaccine; IQR, interquartile range; ICU, intensive care unit.
a
χ 2 test.
b
Kruskal-Wallis test.
c
Information available for 10,786 participants, 943 unvaccinated, 4,749 with 2 doses of CoronaVac vaccine and 5,094 with 2 doses of ChAdOx1 vaccine.
d
Mann-Whitney test.
e
Follow-up was initiated 15 days after the second dose for those vaccinated.
f
Fisher exact test.